Blog: BODY & MIND INC. : Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –

Item 2.02 Results of Operations and Financial Condition.

On January 18, 2023, Body and Mind Inc. (the “Company” or “BaM”) issued a news
release announcing its financial results for the fiscal year ended July 31,
2022. The information regarding the financial results for the fiscal year ended
July 31, 2022 of the Company contained in Item 7.01 below is responsive to this
Item 2.02 and is incorporated into this Item 2.02 by reference.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed
“filed” for purposes of Section 18 of the U.S. Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the U.S. Securities Act of 1933, as amended (the “Securities Act”), or the
Exchange Act, except as expressly set forth by specific reference in such a

Item 7.01 Regulation FD Disclosure.

On January 18, 2023, the Company issued a news release to announce financial
results for the fiscal year ended July 31, 2022 and to provide shareholders with
an operational update. All financial information is provided in U.S. dollars
unless otherwise indicated.

        FY 2022 Summary & Comparison to FY 2021

                                 FY 2022      FY 2021
Revenue                            $31.6        $26.9
Net Income/(Loss)                ($28.2)       ($2.0)
Adjusted EBITDA*                  ($1.4)         $3.9

FY 2022 Highlights:

    ·   Announced two Illinois retail license wins. (See the Company's July 27,
        2022 press release for further details.)
    ·   Completed acquisitions of The Reef dispensary in Seaside, California and
        the Body and Mind-branded dispensary near Cleveland, Ohio.
    ·   Commenced Ohio processing operations to bring Body and Mind branded
        products to the Ohio medical cannabis market.

Subsequent to the end of FY 2022:

    ·   Closed a $3 million unsecured convertible debt financing with Bengal
        Capital and Mindset Capital, two experienced cannabis-focused funds, and
        announced that Bengal Capital partner Josh Rosen would be joining the
        Company's Board of Directors.
    ·   Closed a merger with CraftedPlants NJ, an entity that leases a New Jersey
        retail location with local cannabis-use approval for a retail location and
        is currently working on attaining final state licensure in New Jersey,
        with nearly all merger consideration tied to attainment of specific
        licensing and operational milestones. (See the Company's December 22, 2022
        press release for further details.)


Management Commentary

“As we report the highest annual revenue in BaM’s history, we are excited and
focused on the next stage of our development. Specifically, as we start calendar
2023, we are focused on the following priorities:

    1.  Augmenting Core Accounting Team: As cannabis operators first and foremost,
        we are intentionally spendthrift with respect to overhead expenses. In
        order to improve the timeliness of our financial reporting we are in the
        process of making modest additions to our accounting team.
    2.  Focus Resources on Successful Launch of New Markets: We believe that our
        best return on capital projects in the near to medium term are our two
        recently issued retail cannabis licenses in Illinois and our New Jersey
        retail project.
    3.  Remain Operations-Focused in Existing Markets: We believe our core
        operating ability, both in retail cannabis and craft cultivation, is an
        under-appreciated asset which we are capitalizing on by entering new
        markets in capital efficient ways. We also plan to continue to drive
        operating efficiencies in our existing, more mature markets to hone our
        battle-tested capabilities and to improve our cash flow generation.
    4.  Prudently Evaluate Complementary Opportunities: We remain open to
        augmenting our platform with capital efficient opportunities that map to
        our capabilities, particularly within our newer markets. Given the
        attractiveness of our current projects, we plan to stay patient and only
        pursue opportunities that we believe meet high return thresholds."

“I look forward to updating investors on our advances in line with these
priorities as the year progresses,” stated Michael Mills, CEO of Body and Mind

FY 2022 Financial Highlights:

· Revenues for FY 2022 were $31.6 million, a 17.6 % increase over FY 2021

revenues of $26.9 million.

· Gross profit of $10.9 million for FY 2022 compared to a gross profit of

$12.0 for FY 2021.

· FY 2022 net operating loss was $3.5 million compared to FY 2021 net

operating income $0.6 million. The change in net operating income was

primarily impacted by increased business development, license

applications, new operation startup and a decrease in flower pricing in


· FY 2022 other expenses totalled $22.1 million in expenses compared to $0.4

        million in FY 2021. The largest component of FY 2022 other expenses were
        asset impairment charges related to the Company's carrying value of
        certain goodwill, intangible assets, and right of use assets totalling
        $20.5 million, including impairments of: (1) $10.0 million of all of the
        Company's goodwill related to previous acquisitions; (2) $7.9 million to
        the carrying value of a Company subsidiary's Nevada cannabis licenses; and
        (3) $2.3 million to the right of use assets associated with leased
        Michigan property related to the Company's cancelled plans to enter the
        Michigan cultivation and processing market due to price compression in


· FY 2022 net loss was $28.2 million (or basic and diluted loss per share of

$0.25) compared to a FY 2021 net loss of $2.0 million (or basic and

diluted loss per share of $0.02). The large difference is mostly

attributable to the asset impairments discussed above.

· Adjusted EBITDA loss of $1.4 million for FY 2022 vs. Adjusted EBITDA of

$3.9 million in FY 2021*.

· Total Current Assets were $8.0 million, Total Assets were $31.0 million,

        Total Current Liabilities were $6.6 million and Total Liabilities were
        $20.9 million at July 31, 2022.

The Company had 146,636,974 common shares outstanding as of January 13, 2023.

For further details, please see the Company’s recent Form 10-K filing on EDGAR
at, and the annual audited financial statements filed
on SEDAR at

*Adjusted EBITDA is a Non-GAAP metric used by management that does not have any
standardized meaning prescribed by U.S. GAAP and may not be comparable to
similar measures presented by other companies. Management defines the Adjusted
EBITDA as the Income (loss) from operations, as reported, before interest,
taxes, and adjusted for removing other non-cash items, including the stock-based
compensation expense, gain on settlement, loss on impairment, depreciation, and
further adjustments to remove acquisition related costs or gains. Management
believes Adjusted EBITDA is a useful financial metric to assess its operating
performance on a cash adjusted basis before the impact of non-cash items and
acquisition activities. The most comparable financial measure calculated and
presented in accordance with U.S. GAAP is net operating income (loss), which was
presented above prior to the Adjusted EBITDA figure.

          Net Profit/Loss ($28,228,104)
          Interest Income     ($72,000)
                 Interest    $1,372,208
                      Tax    $2,593,165

Depreciation/Amortization $1,490,516

                   EBITDA ($22,844,215)

                  EBITDA ($22,844,215)
      Gain on settlement      $460,001
      Loss on impairment   $20,517,192
Stock-based compensation      $435,266
         Adjusted EBITDA  ($1,431,756)

Q1 FY2023 Financial Reporting Update

The Company anticipates filing Q1 FY2023 financials during the week of January
23rd, 2023.

A copy of the news release is attached as Exhibit 99.1 hereto.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed
“filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to
the liabilities of that section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act, or the Exchange Act, except as
expressly set forth by specific reference in such a filing.


Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit    Description
  99.1       News Release dated January 18, 2023.
  104      Cover Page Interactive Data File (the cover page XBRL tags are embedded
           within the inline XBRL document)


© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s